Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: pendopharm.com
Number of Employees: -
Year Founded: 2003
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
PendoPharm Inc. develops, manufactures, licenses, and markets branded prescription medicines for health care professionals, pharmacists, and patients in Canada and internationally. It offers allergy, analgesics, cough, cold and sinus, gastroenterology, nasal care, and pediatrics products. It provides MYINFLA, a colchicine repurposed drug for the reduction of atherothrombotic events in adult patients. The company also offers specialty prescription products in therapeutic, such as gastroenterology, orthopedics, and urology. It sells its products through medical and retail sales representatives; wholesale and retail outlets, including pharmacy and mass grocery; affiliates; and distributors. PendoPharm Inc. was formerly known as Pangeo Pharma (Canada) Inc. and changed its name to PendoPharm Inc. in December 2004. The company was founded in 2003 and is based in Montreal, Canada. As of December 31, 2004, PendoPharm Inc. operates as a subsidiary of Pharmascience Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Puglisi, Frank
Head of Business Development and Senior Director
Isber, Jad 
Global Head of Business Development
Vézina, Elise 
Vice-President and Division Head
Lemieux, Jean-François
Interim Vice President and General Manager


Primary Industry Classification
Pharmaceuticals


Primary Office Location
6111 Royalmount | Montreal, QC | H4P 2T4 | Canada
Fax: 514 733 9684

Parent Company
Pharmascience Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Rivex Pharma Inc.
Rivex Pharma Inc. distributes drugs in Canada and internationally. The company offers Klean-Prep, an electrolyte solution to provide bowel cleansing and less abdominal distress; ORTHOVISC and MONOVISC treatments, which reduce joint pains, improve joint mobility, and provide relief from the pain of osteoarthritis of the knee; and Normacol, a bulk forming laxative and a fiber supplement that restores normal bowel action and provides natural relief of occasional constipation. It also provides Imunovir, an immunomodulator of the potentiator type to treat the depression of the immune system, as well as viral infections, such as aolpecia areata, CMV, EBV, hepatitis acute and non-chirrotic chronic active B, influenza, measles and mumps, viral conjunctivitis, subacute sclerosing panencephalitis, HPV, HSV, VZV, and chronic fatigue syndrome. In addition, Rivex Pharma offers regulatory and clinical services, as well as sales, marketing, and logistics services for pharmaceutical companies in Europe and the Americas. The company is based in Aurora, Canada. As of January 25, 2013, Rivex Pharma Inc. operates as a subsidiary of PendoPharm Inc.

United States and Canada
Health Care Distributors
-
-
-
Sublimity Therapeutics Limited
Sublimity Therapeutics Limited operates as a specialty pharmaceutical company that develops therapies for clinical needs in gastrointestinal and immunological diseases and disorders. The company offers various drugs, including CyCol for moderating ulcerative colitis; CyCron, for Crohn’s disease; AlloCol, for the prevention and treatment of graft versus host disease; CyLow, for transplant rejection prevention, psoriasis, and etc.; oral vaccines; oral peptides; SmPill formulations for colon cancer, diarrhea, coeliac disease, and inflammatory bowel disease; and SmPill-enabled combination products for gastrointestinal and immunomodulatory prototypes. It also offers oral pharmaceutical formulation technologies, such as liquid/emulsion drug delivery systems. Sublimity Therapeutics Limited was formerly known as Sigmoid Pharma Limited. The company was incorporated in 2000 and is based in Dublin, Ireland.

Europe
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-29-2014
Sep-29-2014
Private Placement
Buyer
Sublimity Therapeutics Limited
PendoPharm Inc.

6.35
Dec-10-2012
Jan-25-2013
Merger/Acquisition
Buyer
Rivex Pharma Inc.
PendoPharm Inc.
Helix BioPharma Corp. (TSX:HBP)
8.61
Dec-31-2004
Dec-31-2004
Merger/Acquisition
Target
PendoPharm Inc.
Pharmascience Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-07-2023
Product-Related Announcements
The Pendopharm Division of Pharmascience Inc. Recalls One Lot of Rhinaris Nasal Mist Due to Risk of Microbial Growth Which May Lead to Infection
Jul-29-2022
Product-Related Announcements
Pendopharm Launches an Alcohol-Free Antigingivitis Oral Rinse
Sep-22-2021
Product-Related Announcements
PendoPharm Inc. Announces the Canadian Launch of MYINFLA (Colchicine 0.5 Mg Extended-Release Tablets)
May-02-2020
Product-Related Announcements
the Pendopharm Division of Pharmascience Inc. to Recall Two Lots of Axid from the Canadian Market as A Precautionary Measure
Aug-17-2017
Product-Related Announcements
PendoPharm Introduces the New Lax-A Product Line for Relief of Occasional Constipation

Competitors
Acerus Pharmaceuticals Corporation, Amplitude, Inc. (NasdaqCM:AMPL), HLS Therapeutics Inc. (TSX:HLS), Pharmascience Inc., UserTesting, Inc.

M&A Advisors
Davies Ward Phillips & Vineberg LLP


Advisors
M&A Advisors
Davies Ward Phillips & Vineberg LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:18 PM
PendoPharm Inc.
PendoPharm Inc
Reports
33
GlobalData

Jun 15, 2023 06:20 AM
PendoPharm Inc.
PendoPharm Inc
Reports
33
GlobalData

Mar 14, 2023 01:31 AM
PendoPharm Inc.
PendoPharm Inc
Reports
33
GlobalData

Dec 14, 2022 07:57 PM
PendoPharm Inc.
PendoPharm Inc
Reports
35
GlobalData

Nov 16, 2022 05:43 AM
PendoPharm Inc.
PendoPharm Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Sep 19, 2022 05:26 AM
PendoPharm Inc.
PendoPharm Inc
Reports
35
GlobalData

Jul 27, 2022 06:49 AM
PendoPharm Inc.
PendoPharm Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21
GlobalData

Jun 15, 2022 04:06 AM
PendoPharm Inc.
PendoPharm Inc
Reports
34
GlobalData

May 19, 2022 05:20 AM
PendoPharm Inc.
PendoPharm Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
21
GlobalData

Mar 17, 2022 04:08 AM
PendoPharm Inc.
PendoPharm Inc
Reports
34


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
CINGAL

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Puglisi, Frank
Head of Business Development and Senior Director
-
514 733 9684
fpuglisi@pendopharm.com
Isber, Jad 
Global Head of Business Development
-
514 733 9684
jisber@pendopharm.com
Vézina, Elise 
Vice-President and Division Head
-
514 733 9684
evezina@pendopharm.com
Lemieux, Jean-François
Interim Vice President and General Manager
-
514 733 9684
jlemieux@pendopharm.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
